Latest Breaking News On - Gusten danielsson - Page 3 : comparemela.com

Visikol partners with MatTek to leverage their advanced cell culture models in its suite of drug discovery services

Visikol partners with MatTek to leverage their advanced cell culture models in its suite of drug discovery services
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Michael johnsonKostenloser wertpapierhandelErik gatenholmGusten danielssonKevin causeyBusiness developmentVice presidentமைக்கேல் ஜான்சன்கெவின் காரணவணிக வளர்ச்சிதுணை ப்ரெஸிடெஂட்

CELLINK has entered into an agreement to acquire Discover Echo Inc , an innovative and revolutionary microscopy company

CELLINK has entered into an agreement to acquire Discover Echo Inc , an innovative and revolutionary microscopy company
cision.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cision.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoUnited kingdomErik gatenholmGusten danielssonFoley lardnerDuff phelpsEugene choBecho incDiscover echo incDiscover echoConsideration sharesAnnual general meetingNorth americaNasdaq stockholmஒன்றுபட்டது மாநிலங்களில்

CELLINK launches the BIO MDX Series , a scaled-up revolution in biomedical manufacturing

CELLINK launches the BIO MDX Series , a scaled-up revolution in biomedical manufacturing STOCKHOLM, March 15, 2021 /PRNewswire/ CELLINK has announced the launch of the BIO MDX Series, the next generation of bioprinters designed for high-throughput biofabrication and precision 3D bioprinting for biomedical manufacturing, including biocompatible medical devices. Over the past 5 years, as bioprinting has increasingly become the method of choice for researchers in tissue engineering, cell culturing and regenerative medicine, there has been a greater need for improved automation, precision, and reproducibility across fabrication methods. With up to six printheads, nanoliter and picoliter dispensing channels and easy robotic integration, the BIO MDX and BIO MDX+ bioprinters have been specifically designed to meet the demands of the ever-advancing cell-based technologies.

Erik gatenholmGusten danielssonArtur airaBusiness areaஅர்துர் ஐராவணிக பரப்பளவுஉயிர் மருத்துவ

CELLINK AB announces the completion of the offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an overall amount of SEK 3 0 billion

CELLINK AB announces the completion of the offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an overall amount of SEK 3.0 billion Erik Gatenholm, CEO Phone (Sweden): +46 70 991 86 04 Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138 Email: eg@cellink.com Email: gd@cellink.com This is information that CELLINK AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above at 01.30 CET on 12 March 2021. About CELLINK Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to cult

United statesUnited kingdomVastra gotalands lanSouth africaHector martinezGusten danielssonErik gatenholmSetterwalls advokatbyrCitigroup global marketsMattek corporationSwedish companies registration officeFounders of the company erik gatenholmFinancial servicesFrankfurt stock exchangeSullivan cromwellEuropean union withdrawal

Cellink AB announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2 75 billion

Cellink AB announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2.75 billion Erik Gatenholm, CEO Phone (Sweden): +46 70 991 86 04 Phone (US): +1 (650) 515 5566 Phone (US): +1 (857) 332 2138 Email: eg@cellink.com Email: gd@cellink.com This is information that Cellink is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above at 17.50 CET on 11 March 2021. About Cellink Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform hi

United statesUnited kingdomVastra gotalands lanSouth africaHector martinezGusten danielssonErik gatenholmSetterwalls advokatbyrCitigroup global marketsMattek corporationSwedish companies registration officeFounders of the company erik gatenholmFinancial servicesFrankfurt stock exchangeSullivan cromwellEuropean union withdrawal